BOCA RATON, FL–(Marketwire – July 28, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor Chief Medical Officer Dr. Daniel Weiss will present an abstract of the results of a pilot study to test the ability of Vicor’s PD2i^® nonlinear algorithm to detect acute hypovolemia at the AABB 2010 Annual Meeting. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Dr. Weiss will present Mild Hemorrhage Results in Observable Changes in Heart Rate Variability (S106-040B) on October 12, 2010 at 3:15pm in room 339/340, during the session entitled Donor Recruitment, Retention and Adverse Events: Hemoglobin and Iron. The AABB Annual Meeting & CTTXPO 2010 will be held at the Baltimore Convention Center on October 9-12, 2010. 

“We’re honored to have Dr. Weiss’s abstract of our hypovolemia study selected for presentation before this prestigious group. We believe the results achieved by the PD2i^® in this small pilot study suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally. We hope that having the opportunity to share these results with those active in the field of transfusion medicine and cellular technologies worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to detect acute hypovolemia, and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

The study on which the abstract is based was conducted in cooperation with the University of Mississippi Medical Center and Mississippi Blood Services on December 12, 2009 in Smithdale, MS. The goal of the study was to test the ability of Vicor’s PD2i^® nonlinear algorithm to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. All 18 participants in the pilot study were tested prior to donation to determine a baseline PD2i^® value, and re-tested during and after collection. The average PD2i^® value of participants prior to donation was 2.60; the average PD2i^® value following donation was 1.80. With a P value of 0.001, the study results are highly statistically significant; this indicates a better than 99% probability that the results were not achieved randomly.

The AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-12

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) –  Lantronix, Inc. (NASDAQ: LTRX), a leading provider of secure, remote management, device networking and data center management technologies, today announced the worldwide availability of the EDS1100 and EDS2100 Linux software development kit (SDK), furthering its commitment to Linux and strategy for open source computing. The new SDK allows Linux developers to quickly and easily create value-added applications on the EDS1100/2100. Built on the proven, stable 2.6 Linux kernel, the SDK includes a robust set of components for building secure network-enabled products and applications using Linux, one of the world’s most popular open operating systems. Also included in the announcement are firmware updates for the XPort® Pro Linux SDK and MatchPort® AR Linux SDK, available for download at www.Lantronix.com/downloads. 

The EDS1100 and EDS2100 Linux SDK key improvements include:

• uClinux baseline upgrade (Linux kernel 2.6.29);
• IPv6-ready Certification;
• SDK VMWare VM Image to enable developers to build, deploy, customize and maintain Linux applications in a Windows environment;
• Serial-to-Ethernet with SSL and SSH support sample application.

“While we will continue to offer our customers the tools to develop products using our tried and true operating systems, expanding our Linux offerings extends the capabilities of our products for current customer needs and opens up our products to an exponentially wider audience,” said Daryl Miller vice president of engineering for Lantronix. “Every new product we launch will now support Linux.”

The EDS1100/2100 is also available with Lantronix’ powerful operating system, Evolution OS®, which provides end-users a rich, turnkey option with robust functionality right out of the box.

About EDS1100/2100
The EDS1100 and EDS2100 are unique, hybrid Ethernet terminal/multiport device servers which allow remote access to and management of virtually any IT/networking equipment or edge device such as medical equipment, POS terminals or security equipment. Available with Linux and IPv6 or Lantronix’ powerful Evolution OS, the EDS1100/2100 is the best choice when critical data needs to be remotely and securely accessed anywhere, at any time, via the Internet.

For more details on EDS1100/2100, please visit http://www.lantronix.com/device-networking/external-device-servers/eds1100_eds2100.html or contact [email protected].

The Lantronix blog, http://www.lantronix.com/blog, features industry discussion and updates. To follow Lantronix on Twitter, visit http://www.twitter.com/Lantronix

To receive an RSS feed of all Lantronix’ news, please visit http://www.lewiswire.com/us/lewiswire/Lantronix/c/458 and click on subscribe.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a global leader of secure communication technologies that simplify remote access, management and control of any electronic device. Its solutions empower businesses to make better decisions based on real-time information, and gain a competitive advantage by generating new revenue streams, improving productivity and increasing efficiency and profitability. Easy to integrate and deploy, Lantronix products remotely connect and control electronic equipment via the Internet; provide secure remote access to firewall-protected equipment; and enable remote management of IT equipment over the Internet. Founded in 1989, Lantronix serves some of the largest security, industrial and building automation, medical, transportation, retail/POS, financial, government, consumer electronics/appliances, IT/data center and pro-AV/signage entities in the world. The company’s headquarters are located in Irvine, Calif. For more information, visit www.lantronix.com.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – July 27, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF)(PINK SHEETS:APCSF) (the “Company”) announces that, as a result of prevailing market conditions, the private placement financing originally announced on April 15, 2010 (and subsequently revised as disclosed in the Company’s news releases of April 28^th and May 28^th), will not be proceeding on the terms disclosed. The Company is proceeding with a smaller private placement of $325,000 to be used for general corporate purposes by the sale of 3,250,000 share purchase units on a private placement basis, pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange, at $0.10 per unit. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly.

Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm’s length investors, and such insiders’ shareholdings in the Company will increase as a result of any such participation. The revised private placement is intended to close within the next week as soon as the requisite approvals of the TSX Venture Exchange are obtained.

The Company also wishes to clarify that a report on the TSX Venture Exchange website on Tuesday, July 20, 2010 that an insider sold 108,500 shares at $0.12 was not correct. The Company has confirmed that the transaction did not involve a current insider of the Company and was incorrectly designated as such on the TSX Venture Exchange website.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO, ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

DURHAM, NC–(Marketwire – July 27, 2010) –  On the heels of significant Midwest success, Third Degree Advertising is now offering its healthcare-oriented internal communications expertise on a national scale — starting with the East Coast.

“Strong brands start on the inside, and all positive outward change must first be embraced internally,” said Third Degree CEO Roy Page. Third Degree has helped healthcare organizations improve their brands by taking a unique, tailored approach to defining culture and creating opportunities for fruitful conversation between staff and doctors.

One of the key tools for introducing a brand internally is a Culture Book, outlining either a new or updated visual identity as well as the philosophical standards of the strategic branding initiative. “Culture Books can be short and sweet, or comprehensive and corporate,” said Page. 

Jackson County Memorial Hospital
Third Degree worked closely with Jackson County Memorial Hospital to develop their new strategic branding platform, which depended entirely on the buy-in of hospital employees. “This is My Hospital” was launched with an open house event to which staff, patients and community members were invited. Elements of this custom program included an employee Culture Book, a community newsletter, a redeveloped social website, and a Facebook page which helped promote JCMH’s culture both internally and to the community that JCMH serves.

Unity Health Center
Unity Health Center has a strong, community-focused brand. Third Degree developed their positioning: “It starts at the center,” to communicate how patients and employees are at the core of Unity’s commitment to greater health care in the local community. Their internal integrated marketing launch took place in a Unity town-hall style meeting where a brand video, specialty brochure and T-shirts with brand artwork were shared with all levels of staff. The Unity Culture Book, “It Starts with You” informed staff about the new brand and special programs like their teamwork-building paper puzzle pieces and “brag boxes” to recognize co-worker excellence. 

About Third Degree
Third Degree (www.thirddegreeadv.com) fosters more effective doctor-staff communication, and greater patient satisfaction. Third Degree provides strategic marketing research and planning, public relations, media planning and buying, and creative integrated marketing services for print, broadcast, and web-based applications. Based in Oklahoma City, OK and now Durham, NC, the agency works with clients in numerous industries across the U.S.

For more information contact Roy Page at [email protected] or call 1-888-871-3729.

SAN DIEGO, CA–(Marketwire – July 27, 2010) –  SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, today announced that it was named in the top 50 publicly Traded biotech firms by the American Registry. The award was recognized in the San Diego Daily Transcript. The company’s WavSTAT cancer Screening Technology was also recently featured in a cover story in the June 2010 issue of MTI, as a company to watch that is developing and advancing GI diagnostics and screening technologies. Other companies mentioned in the story include Fuji Photo Optical, Olympus Optical and Smiths Group.

According to the article about 20 million endoscopic procedures are performed annually in the U.S. and key factors driving growth in procedures includes the aging population and increasing prevalence of gastrointestinal disorders.

“One of the most exciting areas of technology development for gastroenterology is enhanced imaging modalities,” says author Staylo. “Researchers are continually looking for new ways to improve the accuracy and diagnostic utility of endoscopic screening methods.”

Jim Hitchin, CEO of SpectraScience, said, “We are pleased to have been named in the top 50 publicly traded biotech firms by the American Registry and to also have received significant attention at this year’s Digestive Disease Week (DDW), which led to this article highlighting our technology for the medical community. This shows that SpectraScience is making a name for itself with its state of the art technology.”

Benefits of WavSTAT Technology

• Doesn’t require physical interpretation of screening results, but gives results in objective, standardized format
• Both a therapeutic and diagnostic device so it can remove abnormal tissue at the exact location where it is detected
• Enables physicians to identify where to biopsy rather than perform physical biopsies on a random basis
• Capable of detecting dysplasia at deeper level than other image enhancement technologies

About WavSTAT
The WavSTAT Optical Biopsy System employs a spectrophotometry technique called Laser Induced Fluorescence (LIF) to optically illuminate and analyze tissue using a standard biopsy forceps. The System uses an optical fiber to send cool, safe UV laser light into suspected tissue, where the light reflects back to a computer at different frequencies, depending on the type of tissue. For example, in abnormal tissue, cells fluoresce differently than in healthy tissue and have a different “signature” that our system can interpret as either normal or abnormal. This can greatly assist the physician by providing an additional indication, displaying a green light for normal tissue and a red light for abnormal tissue. If the tissue appears abnormal, physicians can also use the WavSTAT System to biopsy the tissue.

The WavSTAT has FDA clearance to market for detecting pre-cancerous and cancerous tissue in the colon. The Company made several upgrades to its original technology before introducing it at this year’s DDW and launching it in the European market. SpectraScience is planning a full-scale market launch in the US in late 2010 or early 2011. Currently the Company holds approximately 60 patents for its optical probes and underlying technology.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

SAN JOSE, CA–(Marketwire – July 27, 2010) –  NightHawk Radiology Services, which provides high-quality, cost-effective services to approximately 1,600 healthcare sites — including 26 percent of all U.S. hospitals — has selected the Cisco (NASDAQ: CSCO) Unified Computing System® as a highly available and scalable platform for the company’s new main data center, which consolidates many smaller server sites around the country into a single primary site. NightHawk Radiology processes 3 million radiology studies per year with an average turnaround time of under 20 minutes per study, uses the flexible architecture of the Cisco Unified Computing System and its virtualized environment to support its goal of providing best in class radiology services and ensuring patients receive timely service 24 hours a day, seven days a week. The Cisco Unified Computing System unites computational, network, storage access, and virtualization resources in a single energy efficient system that reduces IT infrastructure costs and complexity, helps extend capital assets and improves business agility.

In addition to its impact on customer-facing services, deploying the Cisco Unified Computing System and Nexus 5000 data center switches has resulted in lower costs, easier management, and improved business agility for NightHawk Radiology. With the new system, the IT team reduced servers by 50 percent, reduced the time needed to deploy and manage servers by 80 percent, reduced cabling infrastructure by a factor of five, and can provision servers in just 20 minutes..

KEY FACTS / HIGHLIGHTS

• NightHawk provides a complete suite of high-quality, cost-effective solutions, including professional services, and an advanced, proprietary clinical workflow technology, to increase efficiencies and improve the quality of patient care. NightHawk’s team of U.S. board-certified, state-licensed and hospital-privileged physicians provide radiology healthcare services around the clock, and require a mission-critical data center to support timely information delivery.
• NightHawk has configured eight Cisco Unified Computing System blades as VMware ESX servers, each hosting approximately 10 virtual machines, with plans to double the number of virtual machines in the future. NightHawk also uses the Cisco Nexus 1000V Switch, a software switch that operates inside the VMware ESX hypervisor to give the network team complete visibility into the virtual machine environment for easier management.
• NightHawk Radiology has deployed a full suite of Cisco data center solutions. In addition to the Cisco UCS and Nexus 5000 Series data center switches, the company also deployed Cisco Nexus 2000 Series Fabric Extenders, Cisco MDS storage switches, and the Cisco Catalyst® 4900 Series switch as part of the overall infrastructure. These solutions will enable NightHawk to deploy unified fabric in the data center that is more cost-effective, lower in power and cooling demands, and easier to manage.
• Cisco Services and World Wide Technology supported the project with design, planning and deployment to help NightHawk achieve its goal to design a next-generation system that scales easily and provides investment protection. In addition to the Cisco data center technologies, the solution includes a VMware virtual environment and NetApp storage infrastructure. 
• The Cisco Unified Computing System enables NightHawk to achieve:
  • Competitive Differentiation through High Availability: The Cisco Unified Computing System delivers the high availability that is crucial in an industry where server outages not only cause revenue loss, but also delay delivery of critical patient care. The ease of moving virtual machines between servers helps ensure adequate compute capacity between midnight and 5:00 a.m., when the company receives three-quarters of its images. Server operating system upgrades can be quickly achieved by moving virtual machines to a different blade, and moving them back after. With UCS, Nighthawk no longer has to postpone software updates out of concern for reduced production capacity.
  • Simplified Management: Using the Cisco Unified Computing System Manager service profiles, an administrator can change an operating system configuration and then apply it to multiple server blades at the same time, saving time and reducing configuration errors. Firmware upgrades are easier as well, because the IT team simply attaches the upgrade to the template, and then Cisco UCS Manager automatically updates all server blades associated with that template. This means the IT team can update all servers in just 30 minutes compared to the 20 hours required previously.
  • Lower Costs: NightHawk has made significant cost savings through the need to maintain fewer physical servers as well as halving the number of cables and network interfaces needed to support virtualization. This means more of NightHawk’s power and cooling budgets can be used on servers. 
  • Increased Business Agility: The Cisco Unified Computing System Manager has decreased the time needed to deploy and manage servers by 80 percent, while also increasing stability and availability.

SUPPORTING QUOTES

“Systems availability is a paramount concern in our industry as server outages, even brief ones, can prohibit the delivery of patient care. Because medical practitioners and patients depend on our systems to be 100 percent reliable, we looked for technology with the highest level of redundancy and resiliency. With the Cisco Unified Computing System and Nexus solutions, we’ve experienced extremely high availability, coupled with lower costs and simplified management. Cisco UCS delivers the high availability we need to attract and retain customers.”

-Ken Brande, Vice President, IT, NightHawk Radiology Services

SUPPORTING RESOURCES

• View Cisco Unified Computing website
• Read Cisco Data Center Networks blog
• View Cisco Services
• Read NightHawk Radiology Case Study

Technorati Tags: Cisco, Data Center, Data Center Switches, Unified Computing System, Storage

About Cisco Systems
Cisco (NASDAQ: CSCO), the worldwide leader in networking that transforms how people connect, communicate and collaborate, this year celebrates 25 years of technology innovation, operational excellence and corporate social responsibility. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com.

Cisco, the Cisco logo, Cisco Systems, Cisco Unified Computing System and Catalyst are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

For direct RSS Feeds of all Cisco news, please visit “News@Cisco” at the following link:

http://newsroom.cisco.com/dlls/rss.html

Click here to see all recent news from this company

TAMARAC, FL–(Marketwire – July 27, 2010) –  AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, announced it is initiating a share buyback program in order to lower the outstanding share count and increase shareholder value.

The company’s board of directors is reviewing and wants to purchase shares of AcuMedSpa on the open market and would like to retire those shares back into the treasury. The goal of the program is to purchase up to 10 million shares which will be retired immediately in order to reduce the outstanding shares by the total amount of shares purchased. The current outstanding share total is 146,610,679.

In recent months the company has taken important steps to improve shareholder value by reforming the share structure. Both the outstanding and the authorized shares have been reduced, and decision making power has been given to shareholders over all major decisions including all future share structure changes.

AcuMedSpa Holdings President Gregory Antoine, stated, “This share buyback program is the latest in a series of actions we have taken in our ongoing effort to improve shareholder value. Many small company investors have grown accustomed to share dilution, but we are in effect doing the opposite of dilution by eventually reducing the outstanding shares.” Mr. Antoine continued, “Reduced outstanding shares will benefit the shareholders in several ways and improves the company’s financials. Calculating our earnings with a lower outstanding share total will increase our earnings per share and reflect better on the balance sheet.”

Please follow our progress on twitter: http://twitter.com/acumedinc

For additional info please visit our website: http://www.acumedspa.com/

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AcuMedSpa Holdings, Inc. takes no obligation to update such statements.

KANKAKEE, IL–(Marketwire – July 27, 2010) –  Riverside Medical Center, a south Chicago, Illinois hospital network, is expanding its role as a teaching hospital with the creation of a residency program in Internal Medicine. Riverside also offers fellowships in Gastroenterology and Cardiology. In its inaugural year of the three-year program, the team of residents and various faculty members will work side by side treating patients at various Riverside, Illinois hospital facilities.

“Becoming a teaching hospital really elevates the level of care for the patient and the community,” said Dr. Naresh Chandan, DO, FACOI, FACP, Riverside Medical Center Director of Medical Education and Internal Medicine Program Director. “Not only does it give patients another set of eyes looking out for them, it continues to instill confidence in their care at Riverside. To teach is to learn twice.”

“A residency program at any hospital or clinic is a stage of graduate medical training where physicians, who have received their medical degree, practice under the close supervision of fully licensed physicians. Successful completion of residency training is a requirement to practice medicine independently,” Chandan continues.

Riverside’s Internal Medicine Program provides a holistic learning environment. “The program prepares residents to practice independently in general osteopathic Internal Medicine or to enter into a sub-specialty fellowship program,” said Dr. John Jurica, Riverside Medical Center vice-president of medical affairs.

In addition to an Internal Medicine residency program, Riverside also offers a sub-specialty fellowship in Cardiology and Gastroenterology. The three-year Cardiology fellowship program offers one position per year. The Cardiology Fellowship program will provide exposure to a comprehensive treatment plan, including triple bypass and other related heart center services, and will allow the graduate to practice Cardiology anywhere. The overall goal of the Gastroenterology fellowship program at Riverside is to provide the fellow with a well-balanced experience that is essential for a successful community practice.

“Riverside’s residency program is an investment in our community,” Jurica said. “When the time comes for us to be the patients, we can rest assured knowing that we are receiving the best possible care because of Riverside’s unending commitment to teaching and molding residents into world-class doctors.”

To view more on Riverside Medical Center’s world-class residency program, please visit www.RiversideMC.net/residency.

Click here to see all recent news from this company

BRENTWOOD, MO–(Marketwire – July 26, 2010) –  Scrubs & Beyond, a leading retailer of print and solid scrub tops, jackets, pants, lab coats, shoes and accessories, revealed its fall catalog this week. The highly anticipated fall catalog is set to reach customers across the United States during the week of July 25, 2010 and will offer customers old favorites in addition to new items in a variety of colors, styles and price points. 

Scrubs & Beyond is very excited to be introducing their exclusive S&B solids, starting at just $9.99 each, and S&B print scrubs, starting at $14.99 each. There has never been a better time to stock up for fall. These scrubs are made from soft cotton poplin in both unisex and women’s sizing. Extra details in construction for just the right fit every time, it’s easy for busy medical professionals to mix and match favorite fall colors.

This fall animal print scrubs are one of many must-have items. Customers will find a veritable color safari with fun animal prints from Baby Phat, Cherokee, Los Angeles Rose, Cherokee Flexibles, and Koi. Animal-print seeking fashionistas can also take a walk on the wild side in some great styles in animal-print footwear from Alegria, Nurse Mates and Dansko. Customers will see new offerings from favorite brands such as Koi, Landau, Cherokee, Peaches, Barco, Skechers, Urbane, Scrub Zone, Do No Harm and more. 

Customers have been heard and the call to “Just Give it to Me in Black & White” is here for fall in full force. Scrubs & Beyond’s exclusive black and white scrubs will be a favorite for even the most discriminating Scrubinistas. Koi continues to provide outstanding assortments of styles and prints to mix and match with their essential solid basics and has some great offerings in black and white too! 

As the cooler weather leads into fall, Scrubs & Beyond is ready with value-priced holiday prints to get you in the mood for the season. With so many fashion forward scrubs available for fall, now is the perfect time for medical professionals to shop with Scrubs & Beyond and get exclusive looks that can’t be found anywhere else.

To request the Fall 2010 catalog, or to find a list of all Scrubs & Beyond store locations visit www.ScrubsAndBeyond.com, or call direct at 1-888-255-2668. 

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 26, 2010) –  Every two years, healthcare market research firm Kalorama Information releases the highly anticipated update to its industry leading report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” In seven best-selling editions, Kalorama Information’s lead diagnostic analyst Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing, in one complete volume.

“We’re very pleased to release this completely updated edition of our best-selling title,” said Bruce Carlson, publisher of Kalorama Information. “The idea behind our unique report is that the entire market can be captured in one volume and business planners can use it as a key reference.”

This go-to reference for the IVD industry reveals the trends that are impacting the field now, and provides a realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. All of the major segments of clinical lab testing are covered.

Kalorama has reorganized the presentation of the IVD market in this latest edition in a manner that better reflects how the industry has evolved. For instance, there is an increased focus on lab automation. Due to a lack of trained lab technologists to run the more complex new set of molecular and histological tests and immunoassays, a proliferation of test and lab automation tools has been launched that remove precious human resources from mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones.

“Worldwide Market for In Vitro Diagnostic Tests, 7th Edition” stands as a testament to the Kalorama methodology — real industry knowledge combined with numerous interviews of leading experts in the field and company executives, as well as an exhaustive review of the medical, business, and company literature. More than 900 pages and over 230 key company profiles reveal one vital piece of exclusive industry information after another. The report is available at: http://www.kaloramainformation.com/redirect.asp?progid=79375&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

MILWAUKEE, WISCONSIN–(Marketwire – July 26, 2010) – Extendicare Health Services, Inc. announced today that 27 of its health centers are the proud recipients of the American Health Care Association and the National Center for Assisted Living’s (AHCA/NCAL) Bronze – Commitment to Quality, National Quality Award in recognition of their strong commitment to continuous quality improvement.

The health centers receiving the award are:

“The AHCA/NCAL Quality Awards – comprised of three levels, Bronze – Commitment to Quality award; a more rigorous Silver – Achievement in Quality award; and a comprehensive Gold – Excellence in Quality award – are the most prestigious recognition of quality within the long term care profession,” stated AHCA/NCAL President and CEO, Bruce Yarwood. This Bronze – Commitment to Quality award recognizes dedicated frontline caregivers, administrators, nurses and physicians, who demonstrate their commitment to quality of care in order to meet the needs for our nation’s most vulnerable population.

As a Bronze award recipient, these health centers demonstrated their organization-wide commitment to a customer-focused facility mission, defined its principal customers and their expectations, and indicated ways that they are striving to meet their needs.

“The Quality Award program is an independently judged, criteria-based, award program. This year, only 456 long term care centers nationwide received this noteworthy award and we are pleased to be counted among them. We are proud of this accomplishment and thank our team members for their strong commitment to excellence,” said Tim Lukenda, Chairman and CEO of Extendicare Health Services, Inc.

AHCA/NCAL’s Quality Award is modeled after the criteria of the Malcolm Baldrige National Quality Award, the nation’s premier award recognizing distinguished achievements. AHCA/NCAL’s award is designed to support both continuous quality improvement efforts in long term care by promoting quality awareness and education and to recognize quality achievements.

About Extendicare

Extendicare Health Services, Inc. located in Milwaukee, Wisconsin is a wholly owned subsidiary of Extendicare Real Estate Investment Trust, or Extendicare REIT (TSX symbol “EXE.UN”). Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. 

OAKLAND, CA–(Marketwire – July 26, 2010) –  The Center for Technology and Aging (CTA), is collaborating with the Administration on Aging (AoA) and the Centers for Medicare & Medicaid Services (CMS) on funding innovative care transition projects for older adults and persons with disabilities through the national system of Aging and Disability Resource Centers (ADRC).

CTA’s “Technologies for Improving Post-Acute Care Transitions,” (Tech4Impact) grants are designed to encourage ADRC programs (www.aoa.gov/AoARoot/Grants/Funding/index.aspx) to expand use of technologies that promote better patient transitions from hospitals, rehabilitation centers or nursing facilities back to homes or other community settings.

According to The New England Journal of Medicine, avoidable hospital readmissions within 30 days of discharge cost Medicare $17.4 billion annually.

“We are privileged to be a partner in this national effort to improve care transitions,” said David Lindeman, director of the Center for Technology and Aging. “Improving care transitions and lowering hospital readmissions is a national priority. Use of selected technologies, such as remote patient monitoring and medication management technologies, is associated with reduced hospitalizations, so it makes sense to focus on expanding their use.”

Tech4Impact grants will complement grantee funding made available through the $60 million AoA and CMS initiative, “Implementing the Affordable Care Act: Making it Easier for Individuals to Navigate their Health and Long-Term Care through Person-Centered Systems of Information, Counseling and Access.” Complete details are available at: www.aoa.gov/AoARoot/Grants/Funding/index.aspx.

CTA will make Tech4Impact funds available to states that are awarded grants by AoA/CMS for program Option D: ADRCs Evidence-Based Care Transition Programs. (AoA/CMS grant applications are submitted electronically at www.grants.gov.) The CTA application for states will be released by September 30, 2010, and full proposals will be due October 15, 2010. Grants are expected to commence by January 2011. Additional guidelines pertaining to the Tech4Impact grants are available at www.techandaging.org 

ADRCs (www.adrc-tae.org) are community-based programs designed to streamline access to long-term care services under the auspice of the Administration on Aging, an arm of the U.S. Department of Health and Human Services.

In addition to the Tech4Impact grants, CTA administers grant-funding programs for projects that seek to expand the use of medication optimization and remote patient monitoring technologies for the care of older Americans.

The Center for Technology and Aging (www.techandaging.org) supports the rapid adoption and diffusion of technologies that enhance independence and improve home and community-based care for older adults. Through grants, research, public policy involvement and development of practical tools and best practice guidelines, the Center serves as an independent, non-profit resource for improving the quality and cost-effectiveness of long-term care services. The Center was established with funding from The SCAN Foundation (www.thescanfoundation.org) and is affiliated with the Public Health Institute (www.phi.org) in Oakland, CA.

Click here to see all recent news from this company

ROCKVILLE, MD–(Marketwire – July 26, 2010) –  MarketResearch.com has announced the addition of Business Insights’ new report “Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends,” to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

The pharmaceutical and biopharmaceutical industries are engaged in a business environment which is witnessing a dramatic escalation of R&D costs, key patent expiries, and sustained high attrition rates for new molecules in development.

In response, pharmaceutical companies have recognized the need to expand the range of creative stimuli for their research processes in order to reinvigorate their drug discovery pipelines. Consequently the industry has sought to develop external collaborations not only with other companies but also more frequently with academia, to obtain access to new technologies to enhance their drug discovery capabilities and to in-license candidates for further development. Indeed, collaboration is becoming an essential component of today’s drug discovery efforts and it is commonly undertaken with multiple partners through an often iterative, continuous, and long lasting process, which adds to the complexity of efficiently managing both the collaboration itself and the data generated.

This report explores the opportunities and challenges that are presented by collaboration with university researchers as well as identifying the key inputs from both the industrial and academic partners. The different organizational cultures and structures are examined along with consideration of the goals for each institution and the issues these create. The report discusses the various types of agreement which can be used, highlights legislation of importance to the appropriate protection of intellectual property, and presents case studies of notable collaborations In addition the report offers thoughts on the future for collaborative agreements and the benefits they will bring to both parties.

Questions Answered within the report include…

• What are the key drivers influencing change to a more collaborative approach to R&D in the pharmaceutical industry?
• What are the latest developments in the collaborative approach to R&D and which models represent the best opportunities for the pharmaceutical industry?
• What are the issues and concerns over the evolving collaborative R&D paradigms?
• What are the intellectual property management issues that should be considered by each party?
• Which changes in patent legislation are of greatest relevance to the formation of collaborations in different countries?
• What are the different types of academia-industry collaborations?
• What are the pros and cons for each party in academia-industry collaborations?
• What are the critical success factors for academia-industry collaborations?
• What are the main factors to take into account when negotiating academia-industry collaborations?
• What are the cultural, change management and goal alignment challenges?
• What are the future directions for academia-industry collaborations?

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – July 26, 2010) –  Typenex Medical, LLC, a leader in transfusion recipient verification solutions, has launched their latest barcoded blood band innovation, the FlexiBlood Recipient Verification System.

The FlexiBlood Recipient Verification System was developed using feedback from blood bankers and nurses to ensure that the product improved on the legacy “band and form” recipient verification systems available today. FlexiBlood uses GS1-128 linear barcodes and can accommodate pre-printed patient information labels to reduce transcription errors at the bedside and in the blood bank. It also boasts a barcoded specimen tube sticker that stays attached to the band during application to help promote the accurate labeling of the pre-transfusion specimen at the patient bedside.

“Blood bankers asked for a solution that leverages barcodes to reduce transcription errors and provides a way to help clinical staff label specimens accurately to avoid wrong blood in tube errors,” said Scott Leece, General Manager of Typenex Medical. “Nurses wanted a solution that is easy to use, comfortable for patients, and that supports them throughout the specimen collection and blood administration processes. FlexiBlood was designed to meet all of these requirements.” 

FlexiBlood has additional features that differentiate it from other offerings, such as the ability to be easily reapplied if removed during the patient stay using the Typenex R3 Attachment System and directions for use on every FlexiBlood form. “Based on clinical feedback and the many features of FlexiBlood, we are confident that it is a better solution than Ident-A™ Blood or Securlink®,” stated Leece.

The FlexiBlood Recipient Verification System has two standard forms and six standard insert band colors. For more information on FlexiBlood, please call (866) TYPENEX or visit http://www.typenex.com/. 

About Typenex Medical
Typenex Medical enables hospitals to achieve safer transfusion practices via our suite of recipient verification solutions. These solutions — our Original Alphanumeric Bands, our Next Generation Barcode Bands, and our FlexiBlood Recipient Verification System–provide independent, unique identifiers in various embodiments to help hospitals provide control over their transfusion processes and reduce the costly and dangerous errors associated with blood transfusions. Typenex also improves safety in the laboratory via our TypeSafe™ Segment Sampling Device, which is used to safely pierce blood segments for cross-matching.

Ident-A™ and Securlink® are trademarks of Precision Dynamics Corporation.

MONMOUTH JUNCTION, NJ–(Marketwire – July 26, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13^th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.

The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses’ premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.

Dr. Phillip Chan, Chief Executive Officer and President, commented, “Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients.” 

Dr. Chan continued, “We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of ‘supportive care and watchful waiting’ to one of ‘active treatment,’ potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, the end result of “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial – a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union and then commence clinical trials in the U.S. for approval. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and others. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

ROCKVILLE, MD and SEOUL, SOUTH KOREA–(Marketwire – July 26, 2010) –  Seegene today announced SeePrep™ and SeeCycler™, new clinical instrumentation optimized for Seegene’s multiplex real-time detection tests. SeePrep performs automated magnetic bead nucleic acid extraction, and SeeCycler is an automated detection system for processing samples in real-time. With the addition of these equipment Seegene is now able to provide a complete molecular diagnostic workflow optimized for its multiplex tests, including nucleic acid extraction, amplification, real-time PCR testing and data analysis. The complete system will be on display at the 2010 Annual Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), booth #1800.

“Seegene multiplex real-time PCR products are defining a new era of powerful assays that can rapidly and accurately diagnose a pathogenic infection and genetic mutation. These tests arm medical professionals with the information they need for better and more cost-effective patient care,” said Jong-Yoon Chun, Chief Executive Officer of Seegene. “SeePrep and SeeCycler are the cutting edge in test sample prep and processing, and are a perfect complement to our multiplex testing format. Used together as a complete system, clinicians will benefit from a comprehensive system which simplifies and speeds up the entire test process.”

Seegene is pioneering a new category of multiplex PCR technology that enables the simultaneous detection of viruses and bacteria in a single reaction. Seegene currently has a wide range of assay panels for multiple pathogen screening. The assays primarily target viral and bacterial infections and include panels for viral respiratory infections, sexually transmitted diseases, herpes, diarrhea, HPV, viral meningitis and sepsis.

SeePrep is an automated nucleic acid extraction machine utilizing magnetic bead technology. The hallmark of the instrument is the ability to utilize specimens that are very difficult to extract by any other instrument.

SeeCycler uses patented block dissipation technology for accurate and fast heating and cooling rates, required for better efficiency in DNA amplification, resulting in fast reaction time. It has a capacity of 96 wells and covers and with 6 channels, 5 different analyses can be detected in one sample.

About Seegene

Seegene, Inc. is the leading biotechnology company developing, manufacturing and marketing innovative molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex® and Magicplex® system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.

ATLANTA, GA–(Marketwire – July 26, 2010) –  ALR Technologies Inc. (OTCBB: ALRT) announces that on July 23, 2010 the Company submitted a 510(k) application to the FDA for its proprietary Health-e-Connect (HeC) System. The HeC system is an internet-based product intended for diabetic patients and their health care providers to improve communication and monitoring of patients’ health management programs. One aspect of the system is that HeC will incorporate data uploaded from patients’ glucometers into the ALRT database to quickly assess user compliance and performance compared to provider set targets. The HeC system currently supports data transfer from glucometers manufactured by Abbott, Bayer, Lifescan (a Johnson & Johnson company) and Roche.

In a recently presented clinical evaluation, diabetic patients using the HeC system showed statistically significant improvement in A1c when compared to a control group using standard methods for monitoring and feedback.

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

MENOMONEE FALLS, WI–(Marketwire – July 23, 2010) –  Assisted Living Concepts, Inc. (NYSE: ALC) announced that it plans to release its 2010 second quarter financial results after the New York Stock Exchange closes on Monday August 9, 2010. The release will be posted on ALC’s website at www.alcco.com. ALC has scheduled a conference call on Tuesday August 10, 2010 at 10:00 a.m. (ET) to discuss its financial results for the second quarter. The toll-free number for the live call is (800) 230-1096 or international (612) 332-0107. A taped rebroadcast of the conference call will be available approximately three hours following the live call until midnight on September 10, 2010, by dialing toll free (800) 475-6701 or international (320) 365-3844 and using access code 165684.

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences with capacity for approximately 9,400 residents in 20 states in the United States. ALC’s residences typically consist of 35 to 60 units and offer residents a supportive, home-like setting and assistance with activities of daily living. ALC employs approximately 4,100 people.

LANHAM, MD–(Marketwire – July 23, 2010) –  The Residence at Greenbelt, offering the new standard in modern assisted living, announced today that it will celebrate its grand opening on Tuesday, July 27^th and Wednesday, July 28^th, 2010 from 4pm-7pm. During this monumental two-day event, guests can experience a VIP tour of The Residence on Greenbelt, its new modern models and see first-hand the dignity and vitality of assisted living in a unique community geared towards residents, their families and friends. 

A special tree-planting dedication ceremony will take place on the second day, Wednesday, July 28^th. Samuel H. Dean, Councilman for Ward 6 in Prince George’s County, will lead the dedication of a Southern Magnolia tree that was graciously donated by Behnke Nurseries. Additionally, summer fare and jazz entertainment will be provided both days.

At The Residence on Greenbelt, the warmth and comfort of home and modern convenience come together to define modern assisted living. This unique community offers charm, extensive care and superior care, while allowing residents to experience its modern set of amenities including a Skype lounge and stately movie theatre equipped for the hearing impaired. Conveniently located on Greenbelt Road, The Residence on Greenbelt has recently undergone a complete renovation that has created a vibrant and interesting senior living residence, where residents can experience unrivaled service in modern and fun surroundings.

Three different service programs exist at The Residence on Greenbelt, providing the right match for the needs of seniors. In addition to Assisted Living, the community offers a Special Needs living area that provides for residents with higher acuity and mobility needs in an environment with features focused on maximizing independence while offering comfort and service. The Residence on Greenbelt also provides the Pathways Memory Care Program, an exceptional option for seniors with memory impairments as it offers a stimulating and engaging environment for residents and peace of mind for their families and friends.

For more information about The Residence on Greenbelt, or to attend the Grand Opening event, please call (866) 712-1172 or visit TheResidenceonGreenbelt.com.

About IntegraCare
IntegraCare’s mission is to “improve the quality of life for its employees, residents, and their families.” The company’s goal is to create an environment where its primary customer, the employee, experiences respect, dignity, and personal development. By providing this environment for its employees, the second half of our mission, “improve the quality life for our residents and their families,” will be achieved.

INDIANAPOLIS, IN–(Marketwire – July 23, 2010) –  Health Systems International (HSI), a global provider of outsourced medical cost management solutions, has just received the spotlight in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies — coming in at number 3. View the article at http://www.us-hsi.com/files/Fastest%20Growing%20HSI_July%202010.pdf. This is the second year in a row HSI has received this honor. In 2009, the company appeared on the list at number 9. 

Russell W. Sherlock, Chief Executive Officer of HSI, said, “Our strong sales team and our service results help us to continue to grow even in tough economic times. Healthcare continues to get more complex, and HSI works consultatively with clients to find out how each one can carve dollars out of the healthcare bill. Everyone’s program is unique, and we offer niche services and solutions to fit many markets.”

HSI solutions include cost containment technology and business services customized to meet specific industry needs in the PPO, Maritime, Workers’ Compensation, Property and Casualty, HMO, Health Insurance Carrier, TPA, Self-funded, Reinsurer, and International Health Payor Markets.

About HSI
Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm with over $900 million of equity capital under management. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.us-hsi.com for more information.

NEW YORK, NY–(Marketwire – July 23, 2010) –  (PINKSHEETS: SREH) — SREH Scientific News International (www.scientificnewsroom.com) releases its subscription-based gross revenue projections today as it prepares for an upcoming wave of fall medical conferences for its industry reporting brainchild, www.scientificnewsroom.com.

The projections have been laid out conservatively and factors in a variable attrition rate. “Further,” states CEO Anthony Dibiase, “these figures were calculated with an assumption that only the lower subscription tier was selected by all members. We did this to remain conservative in our projections and even a fraction of doctors choosing to subscribe as premium members would have a significant impact on these numbers. As well, these figures are only based on subscription fees and do not include iPhone app sales, doctor2doctor social networking platform upgrades or doctor2doctor prospective ad revenue.”

SNI Execs are confident it can reach at least 10% of its target market by July 31, 2011 resulting in more than $1 million in gross revenues there. SNI target market includes professionals from all of the major fields the site currently covers: Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology, Urology and Radiology. By year 3, the site expects to reach approximately $5 million in subscription fees alone. “With supplementary medical fields, increased conference attendance, additional iPhone apps and doctor2doctor revenues, we release these projections with the understanding that they are only a fraction of revenues overall for the company. Expanded projections will be released in the near future to reflect additional revenue streams,” comments Dibiase.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was… Fishing, Manga, global tide reports and more! Get your iPhoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iPhone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more! Get ready, as Mobile2Earth unleashes phase 1 of its iPhone app releases for mass consumption.

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

ALEXANDRIA, VA–(Marketwire – July 23, 2010) –  The American Diabetes Association applauds the new White House rule which will help people with diabetes and other chronic diseases appeal the denials of health insurance claims. This rule comes under the new Patient Protection and Affordable Care Act. The rules will help simplify the denial process and create consistency in all 50 states.

“In order to stay healthy, people with diabetes have to manage their disease with supplies like test strips, meters and insulin,” said Nash Childs, PE, Chair of the Board, American Diabetes Association. “Diabetes is a costly disease and without good coverage, the costs can make it difficult to manage properly. It is important that people with diabetes are treated fairly and given the opportunity to appeal any claims that are denied. The American Diabetes Association is grateful to the Obama administration for recognizing the need to make this available to everyone.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

WEST PALM BEACH, FL–(Marketwire – July 22, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a leader among the nation’s hearing care providers, will hold a conference call on Tuesday, August 10, 2010 to discuss results for the second quarter ended June 26, 2010. Financial results will be issued in a press release after the close of the market on the same day.

HearUSA’s Chairman and CEO Stephen J. Hansbrough, President and COO Gino Chouinard, and CFO Frank Puñal will host the call starting at 4:30 p.m. Eastern time. A question and answer session will follow management’s presentation.

To participate in the call, dial the appropriate number 5-10 minutes prior to the start time, request the HearUSA conference call and provide the conference ID: 7HEARUSA.

A Web audio simulcast and replay will be available via the investor relations section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast, please contact Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and will be accessible until August 17, 2010:

About HearUSA
HearUSA is the recognized leader in hearing care for the nation’s top managed care organizations through its 177 company-owned centers and network of more than 2,000 hearing care providers. HearUSA is the nation’s only hearing care provider accredited by URAC, an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation. HearUSA is also the administrator of the AARP Hearing Care program, designed to help millions of Americans aged 50+ who have untreated hearing loss. For more information about HearUSA visit www.hearusa.com, or go to www.hearingshop.com for a wide selection of hearing related products available for purchase online.

BELGRADE, SERBIA–(Marketwire – July 22, 2010) – Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) http://www.htdsmedical.com) is pleased to announce that researchers from its Slavica BioChem (www.slavicabiochem.com) division established the cooperation with world-leading market analysis company from UK.

Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, “The Datamonitor Group (http://www.datamonitor.com/) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor’s healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (http://www.htdsmedical.com) and Slavica BioChem (www.slavicabiochem.com) web sites.

About Mina Mar Group:

Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (www.minamargroup.net), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, “Friday Tips” industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

IRVINE, CA–(Marketwire – July 22, 2010) – For marketing, sales and research professionals who need to understand the complex relationship of physician-to-hospital affiliations, SK&A, A Cegedim Company, today announced the release of an enhancement to its Office-Based Physician database that links practicing physicians to hospitals. SK&A has identified 1,143,420 hospital affiliations for the 680,000 physicians in its industry-leading database. Ninety percent of doctors are affiliated with at least one hospital. The average physician is affiliated with 1.7 hospitals.

SK&A enhanced its database of affiliations by surveying more than 235,000 U.S. medical offices over a six-month period to determine the unique connection between physicians and the hospitals within their sphere of practice or specialty. The survey was conducted by SK&A’s Research Center in Irvine, Calif., as part of its daily telephone verification of medical site information.

“Understanding the distinct and multifaceted relationship between physicians and hospitals is absolutely essential to succeed in today’s competitive marketplace,” said Dave Escalante, SK&A’s Vice President of Data and Information Solutions. “SK&A clients, across 12 major U.S. industries, need this important affiliation information to better plan and execute their sales, marketing and market-research programs. High-quality affiliation data enables more effective selling to physicians, supports enhanced targeting and segmentation, and provides more insight into the complex relationships that influence and drive market behaviors,” continued Escalante.

Through this latest delivery, SK&A has expanded its comprehensive, fully telephone-verified database of affiliation information in healthcare. For example, SK&A has identified 320,197 physicians who are affiliated with group practices. Affiliation coverage includes the ability to accurately identify the sites and personnel within:

• Integrated health systems and networks
• Hospital systems and networks, defined by ownership or affiliation
• Group practice networks
• Affiliated nursing homes
• Affiliated healthcare providers, professionals, administrators, executives and office personnel to health systems, hospitals, group practices, and nursing homes.

All of the affiliation information managed by SK&A, including the newly enhanced
physician-to-hospital affiliations and the baseline reference database, is available in Cegedim Dendrite’s OneKey service.

SK&A clients utilize affiliation information to:

• Deliver more accurate online directories of physicians for patient searches
• Understand the influence health systems and hospitals have on their network (e.g. EHR adoption and pharmaceutical sales rep access to physicians in medical offices)
• Enhance coordinated marketing and sales-resource planning and execution
• Accurately define markets and their overall potential.

About SK&A, A Cegedim Company
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 900,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering. SK&A is part of the France-based Cegedim S.A. Group.

About Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of €874 million in 2009.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit www.cegedim.com.

Click here to see all recent news from this company

ALEXANDRIA, VA–(Marketwire – July 22, 2010) – Darius Gilbert, CEO of Dynamic Solutions, a strength training company, announced that his speed and performance training programs will incorporate the proprietary Movement Training Systems (MTS) Body Position evaluation and performance improvement processes.

As summer training camps and clinics kick into high gear to prepare athletes for the fall sports season, athletes of all ages are looking to increase total body strength and speed in specific sports through strength training. Dynamic Solutions is placing greater emphasis on “movement mechanics.” Movement mechanics are used to teach an athlete how to stabilize position, carry the body in motion, and correctly initiate motion. 

Through its web-based tools, MTS measures flow of muscle reaction from the foot through the entire body which dramatically improves motion, strength, athleticism and speed in young athletes. Through the MTS process, Dynamic Solutions can evaluate the strengths and weaknesses of the individual athlete and structure drills to cue changes for each athlete and increase athletic performance.

“In order to improve speed and performance, we need to measure the initial level of each athlete’s ability,” said Gilbert. “Evaluation becomes our most valuable tool in the process of performance improvement and MTS fills this need.”

“Our goal is to help each athlete be as athletic as possible,” said Vince Stephenson, founder of MTS. “Our system was designed to help athletes, coaches and trainers better understand individual body performance for efficiency.”

Dynamic Solutions and MTS agree that performance is dependent on efficient movement. The best of sport-specific skills are only as good as they can be applied. If an athlete is off-balance, out of position or slow, skills will suffer.

For more information about Dynamic Solutions’ programs, contact: visit www.kettlebellstronginva.com or call 703-209-8696.

For more information about MTS, visit the www.movementtrainingsystems.com or contact [email protected]

id=”nav_links”>

RESTON, VA–(Marketwire – July 22, 2010) –  Santeon Group, Inc. (OTCBB: UBCI) today announced an additional $100,000 contract with the State of Maryland for the latest management process optimization. This represents a continuation of Santeon’s much larger multi-year contract with Maryland for continuous process improvement support through its Business Process Management Suite XIP.

The two new services streamline State operations involved in Healthcare and reduce costs while improving productivity and fraudulent claims:

1. Tracking services provided to patients, verifying specific services are available to patients while also monitoring potential fraud. Also auditors can verify if patients have other insurance that takes seniority for payment of services or if that patient has been previously billed for the service in addition to KDP/BCC. Prior to Santeon’s eCMS process management system, letters were manually typed and mailed to patients, an antiquated solution that was not only costly but time consuming as well.

2. Maryland Health Insurance Plan (MHIP) sends Breast and Cervical a single monthly invoice for paying insurance premiums to selected groups of individuals. The enhanced workflow will determine the types of patients receiving MHIP, and will allow for reviews before and after. In addition, a trail of changes is kept so that BCCDT can provide auditing reports.

Santeon’s CEO Ash Rofail said, “We’re excited to be able to provide cutting edge process management solutions to the State of Maryland. With the successful and timely delivery of this recent enhancement, we expect to leverage significant opportunities for additional revenues from our healthcare division, especially in light of recent federal Healthcare legislation.”

About Santeon Group, Inc.

Santeon Group is a technology company Headquartered in Northern Virginia with offices strategically located in San Diego, Los Angeles, London, Cairo and Dubai. Santeon offers products and services in Healthcare, Energy, Media and Agile Development. Santeon Group provides technically superior end-point process management solutions, streamlining traditional management processes, improving efficiencies and productivity, while reducing the costs of these solutions. For more information please visit the web site at http://www.santeon.com/.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company’s ability to complete a business acquisition. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about UBCI’s future business and financial results, refer to UBCI’s Annual Report on Form 10-K for the year ended December 31, 2009. UBCI undertakes no obligation to update any forward-looking statements that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.

CORAL SPRINGS, FL–(Marketwire – July 22, 2010) –  Willing Holding, Inc. (OTCBB: WHDX) announces that it has completed the acquisition of Accessible Home Health Care.

On July 16, 2010, Willing Holding, Inc. completed the acquisition of the assets of Accessible Home Health Care (www.accessiblehhc.com) from Valiant Healthcare, Inc., a Delaware corporation, through the execution and closing of an Asset Purchase Agreement. Under the reverse merger Valiant (www.valianthealthcare.com) has assumed majority (90%) interest in Willing Holding.

Accessible’s and Valiant’s entire experienced management team has been retained and they continue to run the day to day business of the company.

Accessible’s business model is designed to lead and direct the 21st Century demands of the long term home health care industry by offering a “Complete Home Healthcare Package™” and being a “One Stop Provider™.” Accessible’s primary mission is to provide the highest quality home health care services and products to its patients while adding value to the payers by reducing direct costs and the potential for fraud.

Accessible’s next phase of growth is to expand its company owned units by acquisition of Medicare certified home health care providers in strategic geographic markets.

About Willing Holding, Inc.
Through our Accessible Home Health Care division, we offer and sell a proven one of its kind franchise opportunity to establish and operate a full service medical and personal care Accessible Home Health Care franchise, under our distinctive brand and system. As of July 22, 2010 there are 96 Accessible Home Health Care franchise units and one company-owned unit in 24 states, as well as in India and Kenya.

Forward-Looking Statements
This release is not an offer to purchase or sell securities and may contain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current estimates and projections about Willing Holding, Inc.’s business, which are derived in part on assumptions of its management, and are not guarantees of future performance, as such performance is difficult to predict. The Company assumes no obligation to update information concerning its expectations.